Validation of the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in patients undergoing peripheral endovascular interventions.

ABSTRACT:

Background

It remains unclear whether the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria could apply to peripheral artery disease (PAD) patients undergoing endovascular therapy (EVT).

Aims

We sought to evaluate the application of the ARC-HBR criteria to PAD patients undergoing EVT with contemporary drug-coated devices (DCD) for femoropopliteal artery lesions.

Methods

Between May 2012 and December 2019, 542 consecutive patients undergoing EVT with DCD for femoropopliteal artery lesions were retrospectively analysed. The primary study endpoint was major bleeding events, defined as Bleeding Academic Research Consortium type 3 or 5.

Results

Of 542 patients, 435 (80.3%) were stratified into the HBR group. The cumulative 5-year incidence of ma

SUBMITTER: Tomoi Y 

PROVIDER: S-EPMC10068864 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature